CVN424 for Parkinson's Disease
Trial Summary
What is the purpose of this trial?
This is a randomized, double-blind, placebo-controlled, multicenter study in participants with Parkinson's disease (PD) with motor fluctuations. Participants will be randomized to receive once-daily oral doses of either 75 milligrams (mg) CVN424, 150 mg CVN424, or a matching placebo for 12 weeks. Participants who successfully complete this study and retain eligibility/suitability will be invited to participate in a future open-label extension (OLE) study.
Will I have to stop taking my current medications?
The trial requires that your Parkinson's medications be stable for at least 4 weeks before screening, and certain medications like MAO-B inhibitors need to be stable for 12 weeks. You should not be using strong CYP3A4/5 inhibitors or inducers, or medications with dopamine antagonist activity. It's best to discuss your current medications with the study team to see if any changes are needed.
Eligibility Criteria
This trial is for people with Parkinson's Disease who have motor complications. They must meet specific diagnostic criteria, respond well to levodopa, and experience at least 3 hours of 'OFF' time daily. Participants should be able to walk (with or without help), have a certain cognitive score, maintain stable PD medication use before the trial, and fall within a specified weight range.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive once-daily oral doses of either 75 mg CVN424, 150 mg CVN424, or a matching placebo for 12 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Open-label extension (optional)
Participants may opt into continuation of treatment long-term
Treatment Details
Interventions
- CVN424 (Dopamine Agonist)